HRMY vs ZYME
Side-by-side comparison of price performance, valuation, growth, profitability, analyst targets and technical trend.
HRMY · Harmony Biosciences$33.11 ▲ 1.97%
ZYME · Zymeworks$29.63 ▲ 3.11%
One year, rebased to 100
Each line starts at 100 so growth is directly comparable
- HRMY +4.1%
- ZYME +64.2%
Head to head
| Metric | HRMY | ZYME |
|---|---|---|
| Price | $33.11 | $29.63 |
| Change today | ▲ 1.97% | ▲ 3.11% |
| Market cap | $1.94B | $2.09B |
| Return, 3 months | -15.1% | +22.6% |
| Return, year to date | -11.5% | +12.5% |
| Return, 1 year | +5.3% | +80.0% |
| P/E (TTM) | 11.0 | – |
| P/B | 1.8 | 26.0 |
| P/E percentile vs own 5y | 36th | 21st |
| Dividend yield | – | – |
| Revenue growth (YoY, latest qtr) | +30.3% | -90.6% |
| Net profit growth (YoY) | +89.6% | -2,043.0% |
| Gross margin | 75.4% | – |
| Operating margin | 24.0% | -419.0% |
| Net margin | 18.9% | -404.0% |
| Return on equity | 20.5% | -72.3% |
| Analyst target vs. price | +47.1% | +38.9% |
| Analyst buy share | 71% | 100% |
| RSI (14) | 31 | 59 |
| 30-day volatility | 43.0% | 47.2% |
| Max drawdown, 1 year | -34.5% | -23.6% |
| Trend read | Strong downtrend | Strong uptrend |
| Analyst consensus | Buy | Buy |
Green cells mark the best value in each row where "better" is clear-cut (lower P/E, higher margin). That is a reading of the numbers, not a recommendation. Financials are in each company's reporting currency.
What the numbers say
- ZYME is the largest of the group by market value.
- ZYME has returned the most over the past year.
- HRMY is growing revenue fastest.
- HRMY keeps the most profit per dollar of sales.
- HRMY has been the calmest stock over the last 30 days.